Huan J. Zhu

Anti-human FLT3 monoclonal antibody that inhibits proliferation of monocytic leukemia cell line SHI-1.

W. Xie, songwen Ju, Xue-guang Zhang, 2011, Hybridoma.

MicroRNA expression profile in Treg cells in the course of primary immune thrombocytopenia

Zhuojun Zheng, Yuandong Zhu, Huan J. Zhu, 2019, Journal of Investigative Medicine.

Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis

L. To, A. Roberts, M. Wadleigh, 2011 .

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.

H. Deeg, J. Wood, Z. Estrov, 2009 .

Case Report of acute myeloid leukemia with “WT1, ATRX, CEBPA, CSMD1, IKZF1, and LRP1B mutation and translocation between chromosome 1 and 19” developing from Philadelphia-negative chronic myeloid leukemia after TKI therapy

Wei Wu, Jia Liu, Huan J. Zhu, 2020, Medicine.

A novel treatment regimen of granulocyte colony-stimulating factor combined with ultra-low-dose decitabine and low-dose cytarabine in older patients with acute myeloid leukemia and myelodysplastic syndromes

Jia Liu, Zhuojun Zheng, Huan J. Zhu, 2021, Therapeutic advances in hematology.

Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity.

S. Faria, J. Wood, P. Mclaughlin, 2009 .